Prazosin for PTSD Nightmares: Evidence, Benefits, and Risks
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Prazosin is a prescription medication sometimes used to reduce recurrent, distressing nightmares associated with post-traumatic stress disorder (PTSD). It works by blocking alpha-1 adrenergic receptors involved in the body's response to norepinephrine, a chemical messenger associated with alertness and stress. In the United States, prazosin is approved for hypertension; its use for PTSD-related nightmares is off-label. The research supports considering it for some adults who have persistent PTSD nightmares, with careful attention to blood pressure, tolerability, and the limits of the evidence.
The central clinical distinction is that treating nightmares and treating PTSD as a whole are different goals. The 2023 VA/DoD clinical practice guideline makes a weak recommendation in favor of prazosin specifically for PTSD-associated nightmares while suggesting against it for the overall disorder. A 2025 meta-analysis of 10 randomized trials found improvements in nightmares and insomnia but no statistically significant improvement in global PTSD symptoms. These results support individualized shared decision-making rather than an expectation that everyone will benefit.
What Is Prazosin, and Why Is It Used for PTSD Nightmares?
Prazosin is an alpha-1 adrenergic receptor antagonist originally developed to lower blood pressure. Alpha-1 receptors respond to norepinephrine, which helps regulate vascular tone and participates in arousal-related signaling. Blocking these receptors relaxes blood vessels and can reduce blood pressure. Prazosin also enters the central nervous system, providing a plausible biological basis for its study in trauma-related sleep disturbances. The proposed sleep mechanism is neurobiologically plausible but does not establish exactly why any individual person has nightmares or predict who will respond.
PTSD can involve recurrent dreams connected to a traumatic event, fragmented sleep, heightened arousal, avoidance, intrusive memories, altered mood or cognition, and impaired functioning. A nightmare is one possible symptom, not a diagnostic test. Some people experience chronic nightmares without meeting PTSD criteria, and some people with PTSD have insomnia without recurrent nightmares. Assessment considers the event, symptoms, duration, functional effects, and alternative explanations. The VA/DoD guideline recommends validated clinical assessment rather than diagnosing PTSD from the presence of nightmares alone.
Using prazosin for trauma-associated nightmares is an off-label prescribing decision in the United States. Off-label means the particular use is outside the indication in the FDA-approved product labeling; it does not itself indicate that prescribing is prohibited or scientifically unsupported. The current DailyMed prazosin prescribing information describes the approved blood-pressure indication and its safety warnings. PTSD treatment decisions must take the separate nightmare evidence into account.
Does Prazosin Work for PTSD Nightmares?
Across randomized trials and systematic reviews, prazosin has shown an average benefit for some nightmare outcomes, but individual trial results differ considerably. The best-supported practical conclusion is that a clinician may consider a monitored trial for adults with persistent, distressing PTSD-associated nightmares, particularly when the potential benefit justifies the risk of dizziness, low blood pressure, and medication interactions.
Positive trials and early evidence
Small, controlled trials first reported reductions in recurrent trauma-related dreams and sleep difficulties. In a 2003 double-blind crossover study involving 10 combat veterans, prazosin outperformed placebo on nightmare and sleep-related measures. A later 2008 randomized crossover trial involving 13 civilians with chronic PTSD reported improvement in trauma-related nightmares and some objective sleep measures. These studies provided an important proof of concept; their very small samples and specific clinical populations limit precision and generalizability.
The large negative 2018 veteran trial
A major turning point was the 2018 multicenter randomized trial by Raskind and colleagues. Among 304 military veterans with chronic PTSD and frequent nightmares, prazosin did not significantly outperform placebo for distressing dreams, overall sleep quality, or global clinical improvement at the prespecified assessment. This well-designed study challenged the assumption that promising findings from smaller trials would translate into consistent effectiveness in larger populations.
A negative average trial result does not prove that no one benefits. It does show that improvement during treatment cannot automatically be attributed to the medication, and that benefits vary across settings, participants, and outcome measures. The placebo response, baseline symptom patterns, concurrent care, and medication tolerability all complicate interpretation. Proposed explanations for the different trial results remain hypotheses rather than validated rules for selecting responders.
What meta-analyses show
A 2020 systematic review and meta-analysis pooled six randomized placebo-controlled studies involving 429 participants and found statistically significant average improvements in nightmares, sleep quality, and overall symptom scores. The authors cautioned that study populations and methods varied, and that the evidence rested on a limited number of trials.
The more recent Mendes and colleagues 2025 systematic review and meta-regression included 10 randomized controlled trials comprising 648 people with PTSD. It found an average reduction in nightmare severity compared with placebo (standardized mean difference −0.641; 95% CI −1.200 to −0.082; p=0.025) and improvement in insomnia outcomes (−0.654; 95% CI −1.288 to −0.020; p=0.043). The pooled result for overall PTSD severity was not statistically significant (−0.428; 95% CI −0.902 to 0.046; p=0.077).
These standardized effects summarize differences between groups using different assessment scales. They are not the number of nightmares prevented per week, a percentage chance of success, or a predicted benefit for an individual. Heterogeneity was substantial: the 2025 analysis reported I² values exceeding 80% for the main outcomes. Several constituent trials had some concerns or high risk of bias, and many participants came from veteran samples. The insomnia estimate was sensitive to exclusion of one outlying trial. All of this lowers certainty about how large the true benefit is in a specific patient.
A 2026 clinical review of alpha-1 adrenergic antagonists concluded that prazosin still has the strongest randomized-trial evidence among that class for PTSD-associated nightmares, while acknowledging mixed findings and probable benefit in subsets of patients. That narrative review adds clinical interpretation; it should not be confused with a new large randomized trial.
Why can a drug help nightmares without treating PTSD?
PTSD has multiple symptom domains, and sleep outcomes are narrower than overall clinical recovery. A medication could reduce nightmare distress without substantially changing avoidance, intrusive waking memories, negative trauma-related beliefs, or interpersonal difficulties. In clinical care, improving one disruptive symptom can still be worthwhile when it restores sleep and daytime function, but it does not replace an evidence-based PTSD treatment plan. This distinction underlies the different VA/DoD recommendations for nightmares and global PTSD symptoms.
What Do Current Clinical Guidelines Recommend?
VA/DoD 2023
Recommendation 32 of the VA/DoD 2023 PTSD clinical practice guideline suggests prazosin for nightmares associated with PTSD, rated Weak For, on the basis of low-confidence evidence and a judgment that potential benefits slightly outweigh harms for suitable patients. Recommendation 18 suggests against prazosin for treatment of PTSD overall, rated Weak Against. These recommendations address different treatment outcomes and should be read together.
The 2023 update supersedes the more uncertain nightmare recommendation in the 2017 VA/DoD guideline. Older webpages and summaries may still repeat the former position; publication dates matter when comparing advice. Neither recommendation amounts to a guarantee that the medication will work.
APA 2025
The American Psychological Association's 2025 PTSD treatment guideline addresses evidence-based treatment of PTSD in adults, especially established psychotherapies and broader interventions. Its emphasis should not be interpreted as a medication-specific endorsement of prazosin for nightmares. A clinician considering a nightmare-targeted prescription needs the dedicated drug evidence and safety information alongside wider PTSD guidance.
NICE and the United Kingdom
The NICE NG116 guideline emphasizes trauma-focused psychological interventions and allows certain medications for adults who prefer drug treatment. It does not make an explicit prazosin-specific recommendation for PTSD nightmares in its main recommendations. This is a difference in guideline scope and evidence appraisal, not proof that prazosin is uniformly effective or ineffective.
American Academy of Sleep Medicine
The 2018 American Academy of Sleep Medicine position paper stated that prazosin may be used for PTSD-associated nightmares, while recommending imagery rehearsal therapy for nightmare disorder and PTSD-associated nightmares. That 2018 statement reflected the literature available at that time; newer VA/DoD assessments and systematic reviews provide additional context.
Who Might Be Considered for Prazosin?
The research most directly applies to adults with a clinical history consistent with PTSD and recurrent distressing nightmares. A prescriber would ordinarily establish the severity and frequency of nightmares, their effect on sleep and daily life, whether PTSD has been assessed, what treatments have already been tried, the patient's preferences, and relevant medical factors. The decision is most meaningful when a target outcome can be followed over time.
Important considerations include baseline sitting and standing blood pressure, dizziness or previous fainting, a history of falls, other blood-pressure-lowering medications, sexual-function medications that may lower blood pressure, dehydration, and conditions affecting cardiovascular stability. Other sleep complaints warrant separate evaluation. Loud snoring or witnessed breathing pauses may indicate sleep apnea; dream enactment with injuries may require assessment for other sleep disorders; and substances or other medications may contribute to nightmares.
Prazosin studies have included veterans and civilians, but the relative balance of these groups, as well as sex, age, concurrent medication exposure, and trauma characteristics, differs between trials. Available data are insufficient to promise the same benefit in all groups. Evidence for children and adolescents is far more limited than evidence for adults; the adult trial results should not be presented as pediatric prescribing guidance. The NICE guidance specifically advises against drug treatments for PTSD in people under 18 in its general treatment recommendations.
How Is Prazosin Prescribed and Monitored?
Prazosin for nightmares requires an individual prescription and clinician-led dose adjustment. In trials, doses and schedules varied, and there is no single research-established nightmare dose that is effective and safe for everyone. Prescribers generally account for its blood-pressure effects when choosing an initial dose, changes over time, and timing relative to sleep. The FDA-approved prazosin labeling warns that fainting is particularly important when treatment begins or doses increase and recommends cautious initiation and titration for its approved use.
The meaningful clinical target is reduced frequency, intensity, or distress from trauma-related dreams, along with improved sleep continuity and daytime functioning. A clinician may ask about nights with nightmares, awakenings, daytime dizziness, standing lightheadedness, and actual blood-pressure readings. Sleep or nightmare diaries can help describe changes, but they do not diagnose PTSD and should not drive independent dose adjustments.
An improvement observed after taking prazosin does not establish that the drug alone caused it. Nightmare frequency can change with stress, other treatment, sleep schedules, substances, and the natural course of symptoms. Likewise, an initially disappointing response does not automatically justify raising a dose. Prescribers weigh benefit, tolerability, adherence, and alternative explanations before making changes.
If treatment appears ineffective or causes adverse effects, the appropriate next step is review with the prescriber. People already taking prazosin should not increase, combine, taper, or abruptly stop prescribed medication on the basis of an online article. A plan for stopping or adjusting treatment should consider blood pressure, other indications for the medication, and whether nightmares return.
Side Effects, Warnings, and Drug Interactions
The most clinically important risks arise from lowering blood pressure. Dizziness, lightheadedness upon standing, weakness, headache, and fainting can occur, particularly early in treatment or after dose increases. Fainting can lead to falls and injuries. The DailyMed prescribing information specifically warns about first-dose syncope and additive hypotension with other medications.
Other blood-pressure medicines, diuretics, and some medications used for urinary symptoms may increase the risk of symptomatic hypotension. PDE-5 inhibitors such as sildenafil or tadalafil can also lower blood pressure in combination with prazosin. Alcohol may aggravate dizziness or impaired balance in some people. These interactions call for a review of all prescriptions, over-the-counter drugs, and relevant substances with a prescriber or pharmacist, rather than independent experimentation with dosing intervals.
Less common but serious adverse events are possible. The official drug label includes a warning about priapism, a prolonged erection requiring emergency medical attention if it persists for more than four hours. A person who loses consciousness, experiences a serious fall, develops chest pain, or has other acute concerning symptoms needs prompt medical assessment; emergency services are appropriate when the situation is severe.
Pregnancy, breastfeeding, older age, a history of frequent falls, and important cardiovascular conditions require individualized consideration because safety evidence or physiological vulnerability may differ. Prazosin should not be framed as a harmless sleep supplement. Its original cardiovascular action remains relevant even when prescribed for a mental-health-related symptom.
Can Prazosin Make Nightmares Worse?
Many people who benefit report less disturbing dreaming, but responses vary. An absence of improvement, worsening sleep, or more vivid or distressing dreams warrants a clinical review. Medication timing, concurrent medicines, underlying insomnia, psychological stress, new trauma exposure, and unrelated sleep disorders may help explain changes. The current randomized literature does not establish that worsening nightmares is a common or predictable effect for all prazosin users.
One small 2018 randomized pilot trial among adults with PTSD, nightmares, and suicidal ideation did not find the expected nightmare advantage for bedtime prazosin over placebo. Its small sample and specialized population limit broad generalization. The finding underscores why symptom worsening or emerging safety concerns should be assessed rather than dismissed.
Does Prazosin Help Sleep Quality or Insomnia?
Some trials and reviews show sleep improvement, including the 2025 meta-analysis. Yet insomnia includes difficulty falling asleep, staying asleep, or obtaining restorative sleep for reasons that may extend far beyond nightmares. Reducing trauma-related dreams may help a person's rest while leaving other contributors to insomnia untreated.
For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is an established targeted intervention. It involves a structured clinical approach to sleep habits, unhelpful beliefs about sleep, and maintaining factors. The VA National Center for PTSD discussion of sleep problems discusses assessing sleep problems separately, although its older prazosin recommendation should be interpreted in light of the newer 2023 guideline. A full sleep assessment can consider sleep apnea, restless legs, pain, medications, substance use, circadian factors, and psychiatric comorbidity.
Prazosin Versus PTSD Psychotherapy and Other Medications
Prazosin targets a sleep symptom. Treatments such as prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing (EMDR) address PTSD more broadly through distinct evidence-based therapeutic methods. The 2023 VA/DoD guideline favors established trauma-focused psychotherapies for PTSD treatment when clinically appropriate, with certain pharmacologic options when preferred or indicated. Targeted nightmare management can be part of a wider plan; it is not interchangeable with trauma-focused treatment.
Selective serotonin reuptake inhibitors such as sertraline and paroxetine, and the serotonin–norepinephrine reuptake inhibitor venlafaxine, have a different evidence base for overall PTSD symptoms. They can also have their own adverse effects and effects on sleep. A clinician should consider whether nightmares remain troublesome despite other care, whether a medication already being taken might contribute to unusual dreaming, and whether a separate sleep-focused intervention would be helpful. See PTSD Medications: Benefits, Risks, and Treatment Decisions for the broader medication decision.
Other alpha-1 blockers, including doxazosin, have been discussed as alternatives, but their nightmare evidence is less developed. The 2026 review describes small studies and case reports for several such agents; these are weaker forms of evidence than replicated, adequately powered randomized trials. Neither a similar drug mechanism nor a longer half-life automatically proves equal clinical benefit.
The American Academy of Sleep Medicine position paper supports imagery rehearsal therapy, a structured psychological approach in which distressing dream scripts are therapeutically revised and rehearsed. By contrast, the 2023 VA/DoD guideline judged evidence insufficient for a recommendation for or against several nightmare-focused psychotherapies, including imagery rehearsal therapy. The difference reflects methodologies, evidence selection, and the populations and outcomes assessed. Patients may discuss available psychological options with a qualified clinician rather than assuming one technique works for all nightmares.
What About Benzodiazepines and Combination Treatment?
An exploratory analysis in the 2025 Mendes review found an association between greater benzodiazepine use across studies and larger average improvements in certain sleep or PTSD outcomes. This was a study-level meta-regression, not a randomized comparison of adding a benzodiazepine to prazosin. It cannot establish that the combination is beneficial or safe for a particular person; ecological associations can reflect differences in participant groups and trial protocols.
The VA/DoD guideline recommends against benzodiazepines for treating PTSD because of an unfavorable evidence and risk profile. The exploratory meta-regression does not reverse that recommendation and provides no reason to start or increase a benzodiazepine to make prazosin work better. Concurrent sedatives can also heighten problems such as impaired alertness and falls. Any combination requires individual medical oversight.
What Should Be Checked Before Assuming Nightmares Are Caused by PTSD?
PTSD-related nightmares are often connected in content or emotional character to traumatic experiences, but dreams do not by themselves establish a diagnosis. Nightmare disorder can be diagnosed in its own right. Anxiety, depression, stress, substance use, sleep deprivation, certain medications, and other sleep disorders can also be associated with distressing dreams. Some people have both PTSD and a separate sleep disorder.
A clinical interview distinguishes nightmares from night terrors, sleep paralysis, rapid eye movement sleep behavior disorder, nocturnal seizures, and waking flashbacks. These phenomena have different features, risks, and care pathways. A dream about a distressing event is not sufficient proof of PTSD, nor does an isolated nightmare establish acute stress disorder or another trauma-related diagnosis.
Persistent nightmares accompanied by avoidance, intrusive recollections, negative changes in mood or cognition, sustained threat responses, and impaired functioning merit evaluation by a qualified professional. PTSD classification differs between DSM-5-TR and ICD-11, but both require more than recurrent nightmares. Screening questionnaires may guide evaluation but cannot independently establish the diagnosis. Our related overview, PTSD Screening vs Diagnosis: How Assessment Works, explains the distinction.
Considerations for Different Populations
Veterans and civilians
Much of the randomized prazosin evidence comes from military veteran populations. People exposed to civilian trauma may have different medical histories, concurrent treatments, and patterns of sleep disturbance. Smaller civilian trials provide some supportive evidence, but the overall literature does not establish a reliable treatment-response rule based on military status alone. Clinical assessment should take the person's particular symptoms and circumstances seriously.
Children and adolescents
Adult dosage and effectiveness findings must not be extrapolated into a pediatric treatment instruction. In younger patients, trauma-informed assessment, family support where appropriate, and age-appropriate psychological care are central. The NICE guideline does not recommend drug treatment for PTSD in people under 18. Any off-label pediatric prescription would require specialist judgment and a careful discussion of the limited evidence.
Older adults and people at risk of falls
Orthostatic hypotension can be especially consequential in people with impaired balance, frailty, dehydration, or concurrent antihypertensives. A modest potential reduction in nightmares must be evaluated against the risk of injury from fainting. Review of standing blood pressure, medicines, and fall history is particularly important.
People with complex PTSD or dissociative symptoms
ICD-11 complex PTSD includes PTSD symptoms together with persistent disturbances in self-organization. The evidence base for prazosin remains primarily about nightmares in adults diagnosed with PTSD, not about treating the full range of complex PTSD symptoms or dissociative phenomena. Prazosin cannot be assumed to improve emotional regulation, relationships, or dissociative symptoms simply because nightmares improve.
How to Evaluate Whether a Treatment Trial Is Worth Continuing
Shared decision-making begins with a realistic goal. If nightmares are frequent and severely disrupt sleep, even a partial improvement may matter. The clinician and patient can agree on the symptoms and functional outcomes to review, the adverse effects that should prompt contact, and the point at which the overall benefit-risk balance will be reconsidered.
An appropriate follow-up considers the number of nights affected, the distress and intensity of nightmares, how often sleep is interrupted, daytime alertness, blood-pressure-related symptoms, work or relationship functioning, and any new medications or changes in health. Such monitoring may reveal meaningful improvement, no benefit, or a pattern of adverse effects that outweighs benefit.
If a treatment fails to help, the clinical task is to reassess the diagnosis and sleep picture, check for another sleep disorder or medication effect, review established PTSD treatment, and revisit the person's goals. A poor response to prazosin does not imply that nightmares are untreatable or that the person has an unusually severe or hopeless condition.
Practical Questions to Discuss With a Prescriber
A useful conversation covers how confidently nightmares are linked to PTSD, how treatment success will be measured, baseline blood pressure and fall risk, current antihypertensives or PDE-5 inhibitors, alternative sleep interventions, access to trauma-focused psychotherapy, and a plan for troublesome dizziness or insufficient benefit.
People who are experiencing nightmares can also seek support for sleep safety and regular routines while awaiting evaluation. Avoiding risky self-medication and discussing suspected sleep apnea or dream-enactment injuries are sensible. If nightmares are associated with suicidal thoughts, a crisis evaluation and safety plan take priority over a medication experiment. Prazosin is not an established treatment for suicidality, and the small randomized trial in suicidal patients did not demonstrate a reduction in suicidal ideation.
Frequently Asked Questions
Is prazosin FDA-approved for PTSD nightmares?
No. In the United States, prazosin's labeled indication is hypertension. Clinicians sometimes prescribe it off-label for trauma-related nightmares after weighing the evidence and individual risks. DailyMed prescribing information.
Is prazosin effective for nightmares?
Some randomized trials and pooled analyses show an average reduction in nightmare severity, while a large 2018 trial found no benefit over placebo. The 2025 meta-analysis supports a possible benefit with considerable study heterogeneity. The outcome for an individual person is uncertain.
Does prazosin cure PTSD?
No evidence establishes prazosin as a cure for PTSD. The 2023 VA/DoD guideline distinguishes possible nightmare benefit from insufficient effectiveness for treating overall PTSD. Evidence-based PTSD psychotherapy remains an important treatment consideration.
How long does prazosin take to work for nightmares?
Trial schedules varied, and no universal individual response time is established. A prescriber assesses changes over follow-up while adjusting treatment cautiously when needed. An online timeline should not be used to independently change a dose.
What is the usual prazosin dose for PTSD nightmares?
There is no one universally effective PTSD-nightmare dose established by research. Trials used differing schedules and dose ranges, and the label warns about low blood pressure during initiation and titration. Only the individual prescriber should specify or change a regimen.
Can prazosin cause low blood pressure or fainting?
Yes. Dizziness on standing, low blood pressure, and syncope are clinically important risks, especially when initiating treatment or increasing doses. Other blood-pressure-lowering drugs can heighten the risk. Official safety information.
Can prazosin be taken with antidepressants?
It is sometimes prescribed to people who take other psychiatric medications, but a prescriber must review the full medication list and blood-pressure risks. Research has not established that combining prazosin with an antidepressant improves PTSD outcomes generally, and no single combination is suitable for everyone.
Can prazosin be combined with sildenafil or tadalafil?
These medicines can have additive blood-pressure-lowering effects. This interaction is identified in the DailyMed label. Combination or timing decisions require professional advice.
Is prazosin better than imagery rehearsal therapy?
Direct, high-quality head-to-head evidence does not justify a simple universal ranking. The AASM position paper recommends imagery rehearsal therapy, while the VA/DoD 2023 guideline offers a weak recommendation for prazosin and rates evidence for several psychological nightmare treatments as insufficient. Preferences, availability, and individual needs matter.
Can prazosin treat insomnia without nightmares?
The insomnia literature is mixed and primarily concerns people with PTSD, often with prominent nightmare symptoms. Prazosin should not be treated as a general-purpose sleeping pill. Chronic insomnia calls for assessment of its own causes and consideration of evidence-based insomnia treatment.
Does prazosin work for complex PTSD?
Trials do not establish benefit for the full ICD-11 complex PTSD syndrome. It may be considered for distressing nightmares in an appropriate clinical context, but effects on emotional regulation, self-concept, relationships, or dissociation should not be assumed.
What if prazosin does not help?
Review symptoms, tolerability, treatment goals, medications, and alternative sleep diagnoses with the prescriber. Other nightmare-focused and PTSD treatments may be appropriate. Do not change or discontinue an established medication regimen without an individualized plan.
Key Takeaway
Prazosin is a plausible, guideline-supported option for selected adults with persistent PTSD-associated nightmares. Evidence for reducing nightmares is encouraging at the pooled-study level but inconsistent across individual trials, and it is insufficient to position prazosin as a treatment for PTSD as a whole. Low blood pressure, fainting, drug interactions, and individual preferences are integral to the decision. Effective care joins careful nightmare assessment with appropriate trauma-focused treatment and sleep evaluation.
Related Articles
PTSD Medications: Benefits, Risks, and Treatment Decisions — The broader evidence for medication choices in PTSD and how they relate to trauma-focused therapy.
PTSD Treatment: Evidence-Based Therapy and Medication Options — An overview of established psychotherapies and pharmacologic options for PTSD.
PTSD Screening vs Diagnosis: How Assessment Works — Why symptoms and screening scores require a comprehensive diagnostic evaluation.
References
American Academy of Sleep Medicine. See Morgenthaler et al. (2018), organizational position paper.
American Psychological Association. (2025). Clinical practice guideline for the treatment of posttraumatic stress disorder in adults. Official APA guideline.
DailyMed / U.S. National Library of Medicine. Prazosin hydrochloride capsules: Prescribing information, including warnings, precautions, and interactions. Official drug label.
Mendes, T. P., Pereira, B. G., Coutinho, E. S. F., Melani, M. S., Neylan, T. C., & Berger, W. (2025). Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients: A systematic review and meta-regression analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 136, 111253. https://doi.org/10.1016/j.pnpbp.2025.111253.
Morgenthaler, T. I., Auerbach, S., Casey, K. R., et al. (2018). Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper. Journal of Clinical Sleep Medicine, 14(6), 1041–1055. https://doi.org/10.5664/jcsm.7178.
National Institute for Health and Care Excellence. (2018; current guidance accessed 2026). Post-traumatic stress disorder (NG116): Recommendations. NICE NG116.
Ponomareva, O., Stetson, S. R., Meltzer, B., Kim, K., & Kaplan, G. B. (2026). Effects of prazosin and other alpha-1 adrenergic antagonist drugs on nightmares and sleep disturbances in posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 46(4), 451–461. https://doi.org/10.1097/JCP.0000000000002164.
Raskind, M. A., Peskind, E. R., Kanter, E. D., et al. (2003). Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. American Journal of Psychiatry, 160(2), 371–373. https://doi.org/10.1176/appi.ajp.160.2.371.
Raskind, M. A., Peskind, E. R., Chow, B., et al. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine, 378, 507–517. https://doi.org/10.1056/NEJMoa1507598.
Reist, C., et al. (2021). Prazosin for treatment of post-traumatic stress disorder: A systematic review and meta-analysis. CNS Spectrums. https://doi.org/10.1017/S1092852920001121.
Taylor, F. B., Martin, P., Thompson, C., et al. (2008). Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. Biological Psychiatry, 63(6), 629–632. PubMed PMID 17868655.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. Official full guideline landing page.
U.S. Department of Veterans Affairs, National Center for PTSD. Clinician's guide to medications for PTSD. Official professional resource.